文献速递肝病消化道肿瘤与早癌

膜联蛋白A3阻断增敏肝细胞癌对索拉非尼和瑞戈非尼的疗效

Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
PubMed 文献 · J Hepatol · 2018-06-07

本研究通过凋亡与致瘤性实验分析膜联蛋白A3(ANXA3)赋予肝细胞癌(HCC)细胞索拉非尼耐药的效应,并评估ANXA3/PKCδ介导的p38信号及自噬与凋亡变化。结果显示ANXA3在索拉非尼耐药HCC细胞及患者来源异种移植中富集,过表达抑制PKCδ/p38相关凋亡并激活自噬;抗ANXA3单克隆抗体联合索拉非尼/瑞戈非尼在体内抑制肿瘤生长并显著延长生存。结论认为抗ANXA3联合索拉非尼/瑞戈非尼是HCC治疗新策略,ANXA3可作为预测索拉非尼反应的生物标志物。

要点

  • ANXA3在索拉非尼耐药HCC细胞及患者来源异种移植中富集,赋予HCC细胞索拉非尼耐药。
  • ANXA3过表达抑制PKCδ/p38相关凋亡并激活自噬;ANXA3表达与LC3B正相关且与索拉非尼治疗患者更差总生存相关。
  • 抗ANXA3单克隆抗体联合索拉非尼/瑞戈非尼在体内抑制肿瘤生长并显著延长生存。

核心结论

  • 抗ANXA3治疗联合索拉非尼/瑞戈非尼代表一种新的HCC治疗策略。
  • ANXA3可作为预测索拉非尼治疗反应、对HCC患者进行分层的有用生物标志物。

研究设计与样本

  • 临床前研究:采用凋亡与致瘤性实验分析ANXA3对HCC细胞索拉非尼耐药的功能效应。
  • 通过免疫共沉淀、免疫印迹、免疫荧光和透射电子显微镜评估ANXA3/PKCδ介导的p38信号及自噬与凋亡事件。
  • 通过免疫组织化学评估ANXA3预测索拉非尼反应的预后价值。
  • 在离体和体内研究抗ANXA3单克隆抗体单用或联合索拉非尼/瑞戈非尼治疗HCC的治疗价值。

主要发现

  • ANXA3赋予HCC细胞对索拉非尼的耐药性。
  • ANXA3在索拉非尼耐药HCC细胞和患者来源异种移植中富集。
  • 索拉非尼耐药HCC细胞中ANXA3过表达抑制PKCδ/p38相关凋亡并激活自噬以促进细胞存活。
  • ANXA3表达与HCC中自噬标志物LC3B正相关,并与后续接受索拉非尼治疗患者更差的总生存相关。
  • 抗ANXA3单克隆抗体联合索拉非尼/瑞戈非尼在体内损害肿瘤生长并显著增加生存。

临床怎么用

  • 作者认为抗ANXA3抗体联合索拉非尼/瑞戈非尼的临床研究开发得到这些结果的支持。
  • 作者指出进一步研究将优化患者靶点选择和确定最佳治疗组合。

局限性

  • 原文指出进一步研究将优化患者靶点选择和确定最佳治疗组合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Sorafenib is the only FDA-approved first-line targeted drug for advanced HCC, but its effect on patient survival is limited. Further, patients ultimately present with disease progression. A better understanding of the causes of sorafenib resistance, enhancing the efficacy of sorafenib and finding a reliable predictive biomarker are crucial to achieve efficient control of HCC. METHODS: The functional effects of ANXA3 in conferring sorafenib resistance to HCC cells were analyzed in apoptotic and tumorigenicity assays. The role of ANXA3/PKCδ-mediated p38 signaling, and subsequently altered autophagic and apoptotic events, was assessed by immunoprecipitation, immunoblotting, immunofluorescence and transmission electron microscopy assays. The prognostic value of ANXA3 in predicting response to sorafenib was evaluated by immunohistochemistry. The therapeutic value of targeting ANXA3 to combat HCC with anti-ANXA3 monoclonal antibody alone or in combination with sorafenib/regorafenib was investigated ex vivo and in vivo. RESULTS: ANXA3 conferred HCC cells with resistance to sorafenib. ANXA3 was found enriched in sorafenib-resistant HCC cells and patient-derived xenografts. Mechanistically, overexpression of ANXA3 in sorafenib-resistant HCC cells suppressed PKCδ/p38 associated apoptosis and activated autophagy for cell survival. Clinically, ANXA3 expression correlated positively with the autophagic marker LC3B in HCC and was associated with a worse overall survival in patients who went on to receive sorafenib treatment. Anti-ANXA3 monoclonal antibody therapy combined with sorafenib/regorafenib impaired tumor growth in vivo and significantly increased survival. CONCLUSION: Anti-ANXA3 therapy in combination with sorafenib/regorafenib represents a novel therapeutic strategy for HCC treatment. ANXA3 represents a useful predictive biomarker to stratify patients with HCC for sorafenib treatment. LAY SUMMARY: This study represents the most extensive pre-clinical characterization of anti-ANXA3 monoclonal antibodies for the treatment of hepatocellular carcinoma to date. These results support the clinical trial development of anti-ANXA3 antibodies in combination with sorafenib/regorafenib. Further studies will optimize patient target selection and identify the best treatment combinations.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tong M, Che N, Zhou L, et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018. PMID: 29885413. doi:10.1016/j.jhep.2018.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。